ReviewDer Urologe. Ausg. A2010
[Germ cell cancer--an update].
Review in Der Urologe. Ausg. A, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently a rise in the incidence of testicular germ cell cancer (TGCC) has been repeatedly reported in Germany (18% during the period 2000-2006). Future investigations are needed to examine causes for this increase in TGCT. The mortality rates in the western and eastern parts of Germany converge, but there is still a significantly higher mortality rate in the eastern part. Again future investigations are needed to examine causes for this phenomenon. In cases of testicular microlithiasis, testicular biopsies should be considered if further factors representing testicular dysgenesis syndrome are present, such as infertility, atrophic testes, and undescended testes. One course of adjuvant BEP reduces the risk of relapse by approximately 90% and may be a new option as the initial treatment for all CS1 NSGCT. Patients obtaining a CR (<1 cm) after first-line chemotherapy can be safely observed without PC-RPLND. Relapses are rare and potentially curable with further treatment.
Indexed as
Identifiers
20812045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.